Who is sponsoring NCT02043925?

NCT02043925 is sponsored by KU Leuven.

What condition does NCT02043925 study?

NCT02043925 studies QT-prolongation.

What drugs are being tested in NCT02043925?

Interventions: drugs linked with QT-prolongation.

What is the status of NCT02043925?

NCT02043925 is currently COMPLETED.

Last reviewed 2015-07-27 · How we verify

QT-prolongation in Psychiatric Hospitals

NCT02043925 COMPLETED

Observational study in 6 psychiatric hospitals in Flanders. Patients are included when a QT-prolonging drug is added to a medication profile that already contains a potential QT-prolonging drug. An ECG is taken before the administration of the new drug and a week after starting the new drug to investigate the change in duration of the QTc-interval. Risk factors for developing QT-prolongation and blood concentrations of potassium and creatinine are documented.

Details

Lead sponsor	KU Leuven
Status	COMPLETED
Enrolment	152
Start date	2010-10
Completion	2015-03

Conditions

QT-prolongation

Interventions

drugs linked with QT-prolongation

Primary outcomes

change in QTc-interval (corrected for heart rate) — before and one week after the start of a QT-prolonging drug

Countries

Belgium